Webinar Series: Contamination Control for Cell and Gene Therapy
Explore holistic steps to reduce risk and optimize processes in CGT operations
Cell and gene therapy (CGT) operations share the same contamination control requirements as the broader pharmaceutical industry, which utilizes current good manufacturing practices (cGMP). However, there are unique challenges.
Our four-part educational webinar series explores the heightened risks of contamination in CGT and provides holistic steps that you can take to reduce risk and optimize processes for your operation.
Learning Objectives
During this webinar series, you will:
- Discover how to optimize operations while reducing risk
- Understand processes and techniques to adapt an existing environment for CGT
- Learn about the holistic approach to developing and maintaining your contamination control program
- Find out how to simplify processes to reduce training time
Best Practices for Cell and Gene Therapy Manufacturing
It is vital to establish a robust contamination control program for your CGT manufacturing process to protect your products and increase speed to market. STERIS's best practices document discusses common challenges experienced in CGT manufacturing and how to address them.
